Crescent Biopharma (NASDAQ:CBIO) COO Sells 3,839 Shares of Stock

Key Points

• COO Jonathan McNeill sold 3,839 Crescent Biopharma shares for approximately $64,150 at an average price of $16.71. The transaction was conducted under a Rule 10b5-1 plan to cover tax withholding, leaving him with 134,588 shares.
• Several senior executives collectively sold 16,726 shares worth about $285,501 between September 16 and 18. Because the sales were tax-related and reduced relatively small portions of their holdings, they are viewed as a limited negative signal rather than a clear change in business outlook.
• CBIO rose 0.7% to $16.89, while analysts maintained a generally positive outlook with a consensus “Moderate Buy” rating and an average price target of $29.60. The company reported a quarterly loss of $0.74 per share, in line with expectations.

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) COO Jonathan McNeill sold 3,839 shares of the business's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.71, for a total value of $64,149.69. Following the completion of the transaction, the chief operating officer directly owned 134,588 shares in the company, valued at $2,248,965.48. The trade was a 2.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jonathan Mcneill also recently made the following trade(s):

• On Wednesday, September 16th, Jonathan McNeill sold 731 shares of Crescent Biopharma stock. The shares were sold at an average price of $17.90, for a total value of $13,084.90.
• On Monday, June 22nd, Jonathan McNeill sold 20,549 shares of Crescent Biopharma stock. The shares were sold at an average price of $17.99, for a total value of $369,676.51.

Crescent Biopharma Stock Up 0.7%

CBIO traded up $0.12 during trading on Friday, hitting $16.89. The company's stock had a trading volume of 3,123,507 shares, compared to its average volume of 294,314. The stock has a market capitalization of $627.36 million, a price-to-earnings ratio of -2.51 and a beta of 1.24. The firm's 50 day moving average price is $17.12 and its two-hundred day moving average price is $17.43. Crescent Biopharma, Inc. has a 12 month low of $8.72 and a 12 month high of $27.41.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.74). On average, sell-side analysts forecast that Crescent Biopharma, Inc. will post -2.91 earnings per share for the current year.

Crescent Biopharma News Summary

Here are the key news stories impacting Crescent Biopharma this week:

• Neutral Sentiment: CEO Joshua Brumm, COO Jonathan McNeill, CFO Richard Scalzo, and other insiders collectively sold 16,726 shares worth approximately $285,501 between September 16 and September 18. The sales reduced individual holdings by roughly 0.5% to 3.2%, but insiders continued to retain meaningful positions. SEC insider transaction filing
• Neutral Sentiment: All reported transactions were executed under pre-arranged Rule 10b5-1 trading plans and were described as sales to cover tax-withholding obligations tied to vested equity awards. That reduces the likelihood that the transactions represent a change in management’s outlook, although the aggregate selling may still weigh modestly on sentiment. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by senior executives—including the CEO and COO—could be viewed as a near-term supply or sentiment overhang. However, the relatively small percentage reductions and tax-related rationale make this a limited negative signal rather than a clear indication of weakening business prospects. SEC insider transaction filing

Institutional Trading of Crescent Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. acquired a new stake in shares of Crescent Biopharma during the 4th quarter worth approximately $19,899,000. BVF Inc. IL lifted its holdings in Crescent Biopharma by 98.1% in the fourth quarter. BVF Inc. IL now owns 2,748,763 shares of the biopharmaceutical company's stock valued at $32,600,000 after buying an additional 1,360,900 shares during the period. BlackRock Inc. acquired a new position in Crescent Biopharma in the second quarter valued at approximately $22,892,000. NEXTBio Capital Management LP bought a new position in Crescent Biopharma in the fourth quarter valued at approximately $4,422,000. Finally, Exome Asset Management LLC bought a new position in Crescent Biopharma in the first quarter valued at approximately $2,814,000. 75.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on CBIO shares. HC Wainwright reaffirmed a "neutral" rating on shares of Crescent Biopharma in a research note on Thursday, July 16th. Wedbush reissued an "outperform" rating and issued a $27.00 price target on shares of Crescent Biopharma in a report on Monday. Weiss Ratings restated a "sell (d-)" rating on shares of Crescent Biopharma in a research report on Friday, August 7th. Finally, TD Cowen raised Crescent Biopharma to a "strong-buy" rating in a report on Monday, August 24th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Crescent Biopharma has a consensus rating of "Moderate Buy" and a consensus target price of $29.60.

About Crescent Biopharma

Crescent Biopharma, Inc NASDAQ: CBIO is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company's activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.